Health Care • Medical Specialities
$114.84 ▲ +0.84
(+0.74%)
MKT CAP: $5.42B • VOL: 583.3K
52W L $62 52W H $150
BLLN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $305.1M | $152.6M | $71.7M |
| YoY Revenue Growth % | +100.0% | +112.7% | — |
| Gross Profit | $208.5M | $80.9M | $31.6M |
| Gross Margin % | 68.3% | 53.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $16.0M | -$47.1M | -$69.5M |
| Operating Margin % | 5.3% | -30.9% | -96.9% |
| Net Income (GAAP) | $7.5M | -$41.6M | -$82.7M |
| EBITDA (Normalized) | $23.1M | -$42.8M | -$66.9M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $24.6M | -$41.4M | -$53.7M |
| Capital Expenditures (CapEx) | $8.9M | $5.4M | $3.2M |
| Free Cash Flow (FCF) | $15.7M | -$46.8M | -$56.9M |
| FCF Margin % | 5.2% | -30.7% | -79.3% |
| Return on Invested Capital (ROIC %) | 30.6% | -45.0% | -3.0% |
| Cash & Short-Term Equivalents | $496.0M | $191.5M | $327.8M |
| Total Debt (Short + Long Term) | $57.2M | $51.5M | $697.4M |
| Total Stockholders' Equity | $480.1M | -$251.7M | $1.43B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BLLN.